News | November 09, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Subscribe To Our Newsletter & Stay Updated
